Qiagen N.V.

QGEN

NL0015001WM6

Biotechnology & Medical Research

Market Closed - Nyse Other stock markets 16:00:02 2024-06-27 EDT			5-day change	1st Jan Change
41.1 ^USD	+0.91%		-1.89%	-8.20%

11:57am	Wolfe Research Upgrades Qiagen to Outperform From Peer Perform, Price Target is $50	MT
06-21	Qiagen Seeks M&A	CI

QIAGEN N.V. Reaffirms Sales Guidance for the Fiscal 2019

January 07, 2019 at 04:30 pm

QIAGEN N.V. reaffirmed sales guidance of $30 million for the fiscal 2019.

Latest news about Qiagen N.V.

Wolfe Research Upgrades Qiagen to Outperform From Peer Perform, Price Target is $50	05:57am	MT
Qiagen Seeks M&A	06-21	CI
Transcript : Qiagen N.V. - Shareholder/Analyst Call	06-21
Sartorius on the downswing again - low since 2020 is approaching	06-19	DP
Invest Securities Raises Qiagen PT, Maintains Neutral Rating	06-19	MT
UBS Raises Qiagen Price Target to $46 From $44, Maintains Neutral Rating	06-18	MT
JPMorgan Raises Price Target on Qiagen to $54 From $52, Maintains Overweight Rating	06-18	MT
QIAGEN NV : Gets a Neutral rating from UBS	06-18	ZD
QIAGEN NV : Deutsche Bank reaffirms its Buy rating	06-18	ZD
QIAGEN NV : Berenberg remains its Buy rating	06-18	ZD
Frankfurt shares close: Dax recovers	06-17	DP
Transcript : Qiagen N.V. - Analyst/Investor Day	06-17
Dpa-AFX Overview: COMPANIES from 17.06.2024 - 15:15	06-17	DP
Qiagen Targets 7% Annual Sales Growth Through 2028	06-17	MT
Qiagen eyes sales growth of 7% per year until 2028	06-17	RE
QIAGEN Announces the Release of A New Version of Its Clinical Decision Support Software, QCI Interpret	06-13	CI
Qiagen Scraps NeuMoDx 96, 288 Molecular Systems; Raises 2024 Adjusted Earnings Outlook	06-06	MT
Qiagen to Discontinue NeuMoDx Integrated PCR Testing System	06-06	CI
Qiagen N.V. Reaffirms Earnings Guidance for the Second Quarter of 2024	06-06	CI
Qiagen N.V. Launches Digital PCR Assay Design Tool for QIAcuity, Expands Customization Capabilities of Its Research Platform GeneGlobe	06-05	CI
Qiagen Expands Qiastat-Dx Syndromic Testing Menu in the U.S. with Launch of Molecular Test to Improve Gastrointestinal Care	06-03	CI
Qiagen, Myriad Genetics Team Up to Develop Homologous Recombination Deficiency Test	05-31	MT
Qiagen, Myriad Genetics Partner to Create Easily Distributable Cancer Tumor Test	05-31	MT
QIAGEN and Myriad Genetics Develop Distributable Homologous Recombination Deficiency Test for Global Research and Companion Diagnostics Applications	05-30	CI
Qiagen N.V. Launches New Library Preparation Kit, Facilitating Multiomic Studies and Advancing Precision Medicine	05-29	CI

Qiagen NV is a holding company based in the Netherlands. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.

Sector

Biotechnology & Medical Research

Calendar

2024-08-05 - Q2 2024 Earnings Release (Projected)

Related indices

STOXX EUROPE 600 (EUR) , DAX

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

QIAGEN : A decent start to 2024; guidance unchanged

April 30, 2024 at 09:32 am

More Strategies

Ratings for Qiagen N.V.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

40.73 USD

Average target price

50.37 USD

Spread / Average Target

+23.66%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
QIAGEN N.V.	-8.20%	9.04B
MODERNA, INC.	+21.85%	46.93B
LONZA GROUP AG	+37.63%	39.08B
IQVIA HOLDINGS INC.	-8.05%	38.48B
ALNYLAM PHARMACEUTICALS, INC.	+29.04%	31.01B
CELLTRION, INC.	-13.75%	26.14B
ICON PUBLIC LIMITED COMPANY	+10.65%	25.88B
MEDPACE HOLDINGS, INC.	+38.43%	12.53B
BIO-TECHNE CORPORATION	-6.92%	11.36B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-12.29%	10.65B

Other Biotechnology & Medical Research

Qiagen N.V.

Equities

QGEN

NL0015001WM6

Biotechnology & Medical Research

QIAGEN N.V. Reaffirms Sales Guidance for the Fiscal 2019

Latest news about Qiagen N.V.

Chart Qiagen N.V.

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for Qiagen N.V.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research